Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Challenges With Immunotherapy in Glioblastoma

March 5th 2018

Pearls of Wisdom for the Field of NSCLC

March 1st 2018

Sequencing Therapies for ALK-Rearranged NSCLC

March 1st 2018

New Standard of Care for ALK-Rearranged NSCLC

March 1st 2018

Ongoing Research in EGFR+ NSCLC

March 1st 2018

Treatment of EGFR+ NSCLC Brain Metastases

March 1st 2018

New Standard for Treating Stage 4 EGFR+ NSCLC

March 1st 2018

Biomarkers for Selection of Immuno-Oncology Agents in NSCLC

March 1st 2018

Dual Checkpoint Inhibitor Therapy for NSCLC

March 1st 2018

Quadruple Therapy for Newly Diagnosed NSCLC

March 1st 2018

Immuno-Oncology Combination Therapy: Which Patients With NSCLC?

March 1st 2018

Pembrolizumab + Chemotherapy in Newly Diagnosed NSCLC

March 1st 2018

Checkpoint Inhibitors for Newly Diagnosed Stage 4 NSCLC

March 1st 2018

Potential for Use of Checkpoint Inhibitors in Early-Stage NSCLC

March 1st 2018

Surgery in the Context of Immunotherapy for Locally Advanced NSCLC

March 1st 2018

Treatment of Unresectable Locally Advanced NSCLC

March 1st 2018

Treatment of Operable Locally Advanced NSCLC

March 1st 2018

Improving Outcomes in CRC

February 26th 2018

Progress in CRC Precision Medicine

February 26th 2018

Emerging Immunotherapy Combinations in MSS CRC

February 26th 2018